

=> FILE .CANCER  
COST IN U.S. DOLLARS

FULL ESTIMATED COST

ENTRY	SINCE FILE	TOTAL
SESSION		
	0.00	0.15

FILE 'CANCERLIT' ENTERED AT 11:08:06 ON 10 DEC 2001

FILE 'CAPLUS' ENTERED AT 11:08:06 ON 10 DEC 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 11:08:06 ON 10 DEC 2001

COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:08:06 ON 10 DEC 2001  
COPYRIGHT (C) 2001 BIOSIS(R)

=> S PACLITAXEL AND ALBUMIN

L1 116 PACLITAXEL AND ALBUMIN

=> S L1 AND SOLUB?

L2 18 L1 AND SOLUB?

=> DUP REM L2

PROCESSING COMPLETED FOR L2

L3 8 DUP REM L2 (10 DUPLICATES REMOVED)

=> D 1

L3 ANSWER 1 OF 8 CANCERLIT

DUPLICATE 1

AN 2001175838 CANCERLIT

DN 21175838

TI High affinity binding of paclitaxel to human serum  
albumin.

AU Paal K; Muller J; Hegedus L

CS Department of Pharmaceutical Research and Development, HUMAN Co. Ltd,  
Godollo, Hungary. kpaal@mail.matav.hu

SO EUROPEAN JOURNAL OF BIOCHEMISTRY, (2001). Vol. 268, No. 7, pp. 2187-91.  
Journal code: EMZ. ISSN: 0014-2956.

DT Journal; Article; (JOURNAL ARTICLE)

FS MEDL; L; I

LA English

OS MEDLINE 21175838

EM 200105

=> D 2

L3 ANSWER 2 OF 8 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.  
AN 2001328916 EMBASE

TI Carrier proteins determine local pharmacokinetics and arterial  
distribution of paclitaxel.

AU Lovich M.A.; Creel C.; Hong K.; Hwang C.-W.; Edelman E.R.

CS E.R. Edelman, Harvard-MIT Div. Hlth. Sci./Tech., Massachusetts Inst. of  
Technology, Cambridge, MA 02139, United States. eedelman@mit.edu

SO Journal of Pharmaceutical Sciences, (2001) 90/9 (1324-1335).  
Refs: 45

ISSN: 0022-3549 CODEN: JPMSAE

CY United States

DT Journal; Article

FS 029 Clinical Biochemistry

037 Drug Literature Index

LA English

SL English

=> D 3

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2  
AN 2001:572421 CAPLUS

TI Water-soluble poly-(l-glutamic acid)-Gly-camptothecin conjugates  
enhance camptothecin stability and efficacy in vivo

AU Singer, J. W.; Bhatt, R.; Tulinsky, J.; Buhler, K. R.; Heasley, E.; Klein,  
P.; de Vries, P.

CS Cell Therapeutics, Inc., Seattle, WA, 98119, USA

SO J. Controlled Release (2001), 74(1-3), 243-247

CODEN: JCREEC; ISSN: 0168-3659

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

RE.CNT 8

RE

(1) Cassidy, J; Pharm Cancer Chemother 1993, V17, P315 CAPLUS

(2) Matsumura, Y; Cancer Res 1986, V46, P6387 CAPLUS

(3) Mi, Z; Biochemistry 1994, V33, P10325 CAPLUS

(4) Mi, Z; Biochemistry 1994, V33, P12540 CAPLUS

(5) Muggia, F; Ann NY Acad Sci 1996, V803, P213 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D 4

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 3  
AN 2001:625608 CAPLUS

TI Poly(ethylene glycol)-human serum albumin-paclitaxel  
conjugates: preparation, characterization and pharmacokinetics

AU Dosio, F.; Arpicco, S.; Brusa, P.; Stella, B.; Cattell, L.

CS Dipartimento di Scienza e Tecnologia del Farmaco, Turin, 10125, Italy

SO J. Controlled Release (2001), 76(1-2), 107-117

CODEN: JCREEC; ISSN: 0168-3659

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

RE.CNT 35

RE

(2) Arpicco, S; Bioconjugate Chem 1997, V8, P327 CAPLUS

(3) Boccu, E; Pharmacol Res Commun 1982, V14, P113 CAPLUS

(4) Ceruti, M; J Controlled Release 2000, V63, P141 CAPLUS

(5) Crosasso, P; J Controlled Release 2000, V63, P19 CAPLUS

(7) Delprino, L; J Pharm Sci 1993, V82, P699 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> D 5

L3 ANSWER 5 OF 8 CANCERLIT  
AN 2000213084 CANCERLIT  
DN 20213084  
TI Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel.  
AU Constantinides P P; Lambert K J; Tustian A K; Schneider B; Lalji S; Ma W; Wentzel B; Kessler D; Worah D; Quay S C  
CS SONUS Pharmaceuticals, Bothell, Washington 98021, USA.  
panosc@sonuspharma.com  
SO PHARMACEUTICAL RESEARCH, (2000). Vol. 17, No. 2, pp. 175-82.  
Journal code: PHS. ISSN: 0724-8741.  
DT Journal; Article; (JOURNAL ARTICLE)  
FS MEDL; L; Priority Journals  
LA English  
OS MEDLINE 20213084  
EM 200007

DUPLICATE 4

=> D 6

L3 ANSWER 6 OF 8 CANCERLIT  
AN 2021035353 CANCERLIT  
DN 21035353  
TI Conjugation of camptothecins to poly-(L-glutamic acid).  
AU Singer J W; De Vries P; Bhatt R; Tulinsky J; Klein P; Li C; Milas L; Lewis R A; Wallace S  
CS Cell Therapeutics Inc., 201 Elliott Avenue West, Seattle, WA 98119, USA.  
jsinger@ctiseattle.com  
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (2000). Vol. 922, pp. 136-50.  
Journal code: 5NM. ISSN: 0077-8923.  
DT Journal; Article; (JOURNAL ARTICLE)  
FS MEDL; L; I  
LA English  
OS MEDLINE 21035353  
EM 200103

DUPLICATE 5

=> D 7

L3 ANSWER 7 OF 8 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V. DUPLICATE 6  
AN 97156851 EMBASE  
DN 1997156851  
TI Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate.  
AU Dosio F.; Brusa P.; Crosasso P.; Arpicco S.; Cattel L.  
CS L. Cattel, Dipt. Scienza e Tecnologia Farmaco, University of Torino, v. P.Giuria 9, 10125 Torino, Italy. cattel@ch.unito.it  
SO Journal of Controlled Release, (1997) 47/3 (293-304).  
Refs: 49  
ISSN: 0168-3659 CODEN: JCREEC  
PUI S 0168-3659(97)01656-8  
CY Netherlands

ordered  
JS 9/18/97

DT Journal; Article  
FS 016 Cancer  
030 Pharmacology  
037 Drug Literature Index  
039 Pharmacy  
LA English  
SL English

=> D 8

L3 ANSWER 8 OF 8 CANCERLIT  
AN 96606099 CANCERLIT  
DN 96606099  
TI Immunological studies of Taxol and its functions.  
AU Leu J  
CS Columbia Univ.  
SO Diss Abstr Int [B], (1995). Vol. 56, No. 1, pp. 186.  
ISSN: 0419-4217.  
DT (THESIS)  
FS ICDB  
LA English  
EM 199605

=> FIL STNGUIDE

COST IN U.S. DOLLARS

FULL ESTIMATED COST

ENTRY	SINCE FILE	SESSION	TOTAL
	13.63		13.78

FILE 'STNGUIDE' ENTERED AT 11:11:46 ON 10 DEC 2001  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Dec 7, 2001 (20011207/UP).

=> LOGOFF HOLD


COST IN U.S. DOLLARS

FULL ESTIMATED COST

ENTRY	SINCE FILE	SESSION	TOTAL
	0.00		13.78

SESSION WILL BE HELD FOR 60 MINUTES

::r:qu:j{  
(:b:STNGUIDE t:b::  
::r:r-b:b-:  
:b::B:b::q::  
::b::31156459 5/0/H/UD/10DEC2001/112426/31156459/SSSPTA16/47SXW/:{DINI:::  
:B: 47SX  
T2/5/0/H/UD/10DEC2001/112426/31156459/SSSPTA16/47SXW/STNGUIDE/(NONE)/0.24/::::  
31156459 0.24:h::::FULL ES 0.00g::-:&  
::r:  
::r:qu:j{  
(:b



# INTERNATIONAL SEARCH REPORT

national Application No  
PCT/HU 98/00086

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K47/42 A61K9/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 326 618 A (NIPPON HYPOX LAB INC) 9 August 1989  see page 3, line 18-28 see page 5, line 12-17 see page 6, line 1 see page 7, line 3 see page 9, line 13-25 see claims 1,4	1,2,4-7, 23-28, 30,33, 35,38
X	PATENT ABSTRACTS OF JAPAN vol. 008, no. 062 (C-215), 23 March 1984 & JP 58 216126 A (ONO YAKUHI KOGYO KK), 15 December 1983 see abstract	1,2,4-7

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date of priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

5 November 1998

Date of mailing of the international search report

11/11/1998


Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

La Gaetana, R

Form PCT/ISA/E10 (second sheet) (July 1992)



# INTERNATIONAL SEARCH REPORT

national Application No  
PCT/HU 98/00086

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 37 02 105 A (BAYER AG) 4 August 1988 cited in the application see claims see page 2, line 64 - page 3, line 7	1,2,4
P,X	WO 98 28011 A (SCHERING CORP) 2 July 1998 see page 2, line 21-32 see page 6, line 5-10 see page 6, line 19-21 see page 6, line 37-39 see page 25, line 9-22 see example 7 see claim 1	1-4
P,A	WO 98 14174 A (SOON SHIONG PATRICK ;TAO CHUNLIN (US); YANG ANDREW (US); DESAI NEI) 9 April 1998 see page 11, line 22 - page 12, line 5 see page 12, line 15-25 see page 14, line 9-23 see page 17, line 13 - page 18, line 34 see page 22, line 1 - page 28, line 37 see claims 1-7	1-41

1

Form PCT/BA210 (continuation of second sheet) (July 1992)